219 related articles for article (PubMed ID: 31724304)
1. Clinical profile and outcome of classical Hodgkin lymphoma treated with a risk-adapted approach in a tertiary cancer center in India.
Parambil BC; Narula G; Prasad M; Shah S; Shet T; Shridhar E; Khanna N; Laskar S; Gujral S; Sankaran H; Banavali S
Pediatr Blood Cancer; 2020 Feb; 67(2):e28058. PubMed ID: 31724304
[TBL] [Abstract][Full Text] [Related]
2. Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial.
Mauz-Körholz C; Landman-Parker J; Balwierz W; Ammann RA; Anderson RA; Attarbaschi A; Bartelt JM; Beishuizen A; Boudjemaa S; Cepelova M; Claviez A; Daw S; Dieckmann K; Fernández-Teijeiro A; Fosså A; Gattenlöhner S; Georgi T; Hjalgrim LL; Hraskova A; Karlén J; Kluge R; Kurch L; Leblanc T; Mann G; Montravers F; Pears J; Pelz T; Rajić V; Ramsay AD; Stoevesandt D; Uyttebroeck A; Vordermark D; Körholz D; Hasenclever D; Wallace WH
Lancet Oncol; 2022 Jan; 23(1):125-137. PubMed ID: 34895479
[TBL] [Abstract][Full Text] [Related]
3. Children and Adolescent Hodgkin Lymphoma in Argentina: Long-term Results After Combined ABVD and Restricted Radiotherapy.
Zubizarreta PA; Alfaro E; Guitter M; Sanchez La Rosa C; Galluzzo ML; Millán N; Fiandrino F; Felice MS
J Pediatr Hematol Oncol; 2017 Nov; 39(8):602-608. PubMed ID: 28902084
[TBL] [Abstract][Full Text] [Related]
4. Risk-adapted therapy with three or six cycles of doxorubicin/bleomycin/vinblastine/dacarbazine plus involved-field radiation therapy in Hodgkin lymphoma, based on prognosis at diagnosis and early response: results from the GATLA study.
Pavlovsky S; Corrado C; Pavlovsky MA; Prates MV; Zoppegno L; Giunta M; Cerutti I; Palomino E; Pagani F; Lastiri F; Bar D; Bezares RF; Avila G
Clin Lymphoma Myeloma Leuk; 2010 Jun; 10(3):181-5. PubMed ID: 20511162
[TBL] [Abstract][Full Text] [Related]
5. Retrospective analysis of clinical features and treatment outcomes of children with Hodgkin's Lymphoma treated with different chemotherapy protocols at a tertiary care center in Pakistan.
Mehreen A; Wali RM; Sindhu II; Asad M; Ria S
J Pak Med Assoc; 2019 Sep; 69(9):1266-1272. PubMed ID: 31511710
[TBL] [Abstract][Full Text] [Related]
6. The Utility of PET/CT in Guiding Radiotherapy Reduction for Children With Hodgkin Lymphoma Treated With ABVD.
Ingley KM; Nadel HR; Potts JE; Wilson DC; Eftekhari A; Deyell RJ
J Pediatr Hematol Oncol; 2020 Mar; 42(2):e87-e93. PubMed ID: 31259825
[TBL] [Abstract][Full Text] [Related]
7. Treatment of Early-Stage Unfavorable Hodgkin Lymphoma: Efficacy and Toxicity of 4 Versus 6 Cycles of ABVD Chemotherapy With Radiation.
Gunther JR; Fanale MA; Reddy JP; Akhtari M; Smith GL; Pinnix CC; Milgrom SA; Yehia ZA; Allen PK; Osborne EM; Mawlawi O; Dabaja BS
Int J Radiat Oncol Biol Phys; 2016 Sep; 96(1):110-8. PubMed ID: 27325479
[TBL] [Abstract][Full Text] [Related]
8. ABVD or BEACOPP
Fermé C; Thomas J; Brice P; Casasnovas O; Vranovsky A; Bologna S; Lugtenburg PJ; Bouabdallah R; Carde P; Sebban C; Eghbali H; Salles G; van Imhoff GW; Thyss A; Noordijk EM; Reman O; Lybeert MLM; Janvier M; Spina M; Audhuy B; Raemaekers JMM; Delarue R; Anglaret B; de Weerdt O; Marjanovic Z; Tersteeg RJHA; de Jong D; Brière J; Henry-Amar M; ;
Eur J Cancer; 2017 Aug; 81():45-55. PubMed ID: 28601705
[TBL] [Abstract][Full Text] [Related]
9. Does Interim PET Scan After 2 Cycles of ABVD Predict Outcome in Hodgkin Lymphoma? Real-World Evidence.
Seshachalam A; Karpurmath SV; Rathnam K; Raman SG; Janarthinakani M; Prasad K; Patil C; Anoop P; Reddy N; Anumula SK; Roopa SP; Golamari KR; Danthala M; Gunari P; Malipatil B; Rangarajan B; Udupa KS; Nandennavar M; Niraimathi K; Shewade HD
J Glob Oncol; 2019 Nov; 5():1-13. PubMed ID: 31834832
[TBL] [Abstract][Full Text] [Related]
10. ABVD-Based Therapy for Hodgkin Lymphoma in Children and Adolescents: Lessons Learnt in a Tertiary Care Oncology Center in a Developing Country.
Jain S; Kapoor G; Bajpai R
Pediatr Blood Cancer; 2016 Jun; 63(6):1024-30. PubMed ID: 26855007
[TBL] [Abstract][Full Text] [Related]
11. Excellent Outcomes Following Response-based Omission of Radiotherapy in Children and Adolescents With Intermediate or High-risk Hodgkin Lymphoma.
Ozuah NW; Marcus KJ; LaCasce AS; Billett AL
J Pediatr Hematol Oncol; 2018 Aug; 40(6):e338-e342. PubMed ID: 29293187
[TBL] [Abstract][Full Text] [Related]
12. Eight Cycles of ABVD Versus Four Cycles of BEACOPPescalated Plus Four Cycles of BEACOPPbaseline in Stage III to IV, International Prognostic Score ≥ 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial.
Carde P; Karrasch M; Fortpied C; Brice P; Khaled H; Casasnovas O; Caillot D; Gaillard I; Bologna S; Ferme C; Lugtenburg PJ; Morschhauser F; Aurer I; Coiffier B; Meyer R; Seftel M; Wolf M; Glimelius B; Sureda A; Mounier N
J Clin Oncol; 2016 Jun; 34(17):2028-36. PubMed ID: 27114593
[TBL] [Abstract][Full Text] [Related]
13. Treating early-stage Hodgkin lymphoma in resource-limited settings: InPOG-HL-15-01 experience.
Mahajan A; Singh M; Bakhshi S; Jain S; Radhakrishnan V; Verma N; Seth R; Arora RS; Dinand V; Kalra M; Mandal P; Kapoor G; Sajid M; Thulkar S; Arora A; Taluja A; Chandra J
Pediatr Blood Cancer; 2021 Oct; 68(10):e29219. PubMed ID: 34291860
[TBL] [Abstract][Full Text] [Related]
14. Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern era.
Jalali A; Ha FJ; Chong G; Grigg A; Mckendrick J; Schwarer AP; Doig R; Hamid A; Hawkes EA
Ann Hematol; 2016 Apr; 95(5):809-16. PubMed ID: 26878861
[TBL] [Abstract][Full Text] [Related]
15. An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma.
Hay AE; Klimm B; Chen BE; Goergen H; Shepherd LE; Fuchs M; Gospodarowicz MK; Borchmann P; Connors JM; Markova J; Crump M; Lohri A; Winter JN; Dörken B; Pearcey RG; Diehl V; Horning SJ; Eich HT; Engert A; Meyer RM;
Ann Oncol; 2013 Dec; 24(12):3065-9. PubMed ID: 24121121
[TBL] [Abstract][Full Text] [Related]
16. [A single-center retrospective analysis of 85 children and adolescents with limited-stage Hodgkin lymphoma].
Wu B; Wang J; Zhu J; Zhen ZZ; Lu SY; Sun FF; Huang JT; Sun XF
Zhonghua Xue Ye Xue Za Zhi; 2020 Aug; 41(8):649-654. PubMed ID: 32942818
[No Abstract] [Full Text] [Related]
17. Outcomes in intermediate-risk pediatric lymphocyte-predominant Hodgkin lymphoma: A report from the Children's Oncology Group.
Marks LJ; Pei Q; Bush R; Buxton A; Appel B; Kelly KM; Schwartz CL; Friedman DL
Pediatr Blood Cancer; 2018 Dec; 65(12):e27375. PubMed ID: 30277639
[TBL] [Abstract][Full Text] [Related]
18. Characteristics and Survival Outcomes of Children With Hodgkin Lymphoma Treated Primarily With Chemotherapy.
Ashraf MS; Naz F; Yakoob MY
J Pediatr Hematol Oncol; 2019 Aug; 41(6):452-456. PubMed ID: 31033793
[TBL] [Abstract][Full Text] [Related]
19. Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome.
Savage KJ; Skinnider B; Al-Mansour M; Sehn LH; Gascoyne RD; Connors JM
Blood; 2011 Oct; 118(17):4585-90. PubMed ID: 21873543
[TBL] [Abstract][Full Text] [Related]
20. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study.
Mauz-Körholz C; Hasenclever D; Dörffel W; Ruschke K; Pelz T; Voigt A; Stiefel M; Winkler M; Vilser C; Dieckmann K; Karlén J; Bergsträsser E; Fosså A; Mann G; Hummel M; Klapper W; Stein H; Vordermark D; Kluge R; Körholz D
J Clin Oncol; 2010 Aug; 28(23):3680-6. PubMed ID: 20625128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]